Cantor analyst Daniel Brims was out pounding the table on Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) Thursday, reiterating a Buy rating and price target of $14, …
Thomas Yip, equity research analyst at MLV & Co., weighed in today with a favorable report on Threshold Pharmaceuticals, Inc.
Cantor’s healthcare analyst Daniel Brims came out with a few insights on Threshold Pharmaceuticals, Inc. (NASDAQ:THLD), after the company hosted an Analyst and Investor Day on April …
In a research report released Tuesday, MLV analyst Thomas Yip maintained a Buy rating on Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) with a $14.
